Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 May;11(Suppl 9):S1270-S1273.
doi: 10.21037/jtd.2019.05.07.

Terlipressin or norepinephrine in septic shock: do we have the answer?

Mark D Williams  1 , James A Russell  2
Affiliations
Editorial

Terlipressin or norepinephrine in septic shock: do we have the answer?

Mark D Williams et al. J Thorac Dis. 2019 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Williams reports consulting fees in the last 3 years from Ferring (selepressin), AKPA (recombinant soluble thrombomodulin) and Lajolla Pharmaceuticals (angiotensin II). Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell was a founder, Director and shareholder in Cyon Therapeutics Inc. Dr. Russell is a shareholder in Molecular You Corp (in the last 36 months). Dr. Russell reports receiving consulting fees in the last 3 years from: (I) Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin in sepsis). (II) SIB Therapeutics LLC (developing a sepsis drug). (III) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin).

Comment in

Comment on

References

    1. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017;45:486-552. 10.1097/CCM.0000000000002255 - DOI - PubMed
    1. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016;316:509-18. 10.1001/jama.2016.10485 - DOI - PubMed
    1. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. 10.1056/NEJMoa067373 - DOI - PubMed
    1. Russell JA, Vincent JL, Kjolbye AL, et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 2017;21:213. 10.1186/s13054-017-1798-7 - DOI - PMC - PubMed
    1. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017;377:419-30. 10.1056/NEJMoa1704154 - DOI - PubMed